Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A note on sample size calculation based on propensity analysis in nonrandomized trials.

Sin-Ho Jung1, Shein-Chung Chow, Eric M Chi

  • 1Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA. sinho.jung@duke.edu

Journal of Biopharmaceutical Statistics
|January 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

Research square·2026
Same author

The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Future oncology (London, England)·2026
Same author

Power Calculation for Non-inferiority Test Based on Linear Combination of Two Correlated Binary Endpoints.

Therapeutic innovation & regulatory science·2026
Same author

Controversial issues in clinical investigation of rare disease drug development.

Journal of biopharmaceutical statistics·2026
Same author

Switching Design for Assessment of Interchangeability in Biosimilar Studies.

Pharmaceutics·2026
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study introduces a new sample size formula for nonrandomized trials, addressing treatment imbalance using propensity score analysis. The formula enhances statistical power for weighted Mantel-Haenszel tests, improving clinical trial design.

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Epidemiology

Background:

  • Nonrandomized trials often suffer from treatment imbalance due to non-equal patient assignment probabilities based on covariates.
  • This imbalance compromises the comparability of treatment groups, a critical issue in clinical research.
  • The United States Food and Drug Administration (FDA) recommends propensity score analysis to mitigate these imbalances.

Purpose of the Study:

  • To develop a novel formula for sample size calculation in nonrandomized trials.
  • To address the challenge of treatment imbalance in clinical studies.
  • To provide a statistical tool that improves the reliability of findings from observational studies.

Main Methods:

  • A sample size formula was derived based on a proposed weighted Mantel-Haenszel test.

Related Experiment Videos

  • The test operates on strata defined by propensity score analysis.
  • The derivation accounts for the complexities of nonrandomized treatment assignment.

    • Main Results:

    • A new formula for sample size calculation was successfully developed.
    • The proposed formula offers a method to determine adequate sample sizes in the presence of treatment imbalance.
    • It was demonstrated that a previously established formula (Nam, 1998) is a specific instance of the newly derived formula.

    Conclusions:

    • The developed sample size formula provides a valuable tool for researchers conducting nonrandomized trials.
    • This method aids in achieving comparable treatment groups through propensity score analysis and weighted Mantel-Haenszel tests.
    • The findings contribute to more robust statistical planning for clinical studies aiming to overcome treatment imbalance.